Security
Protagenic Therapeutics, Inc. Common Stock · PTIX
PTIXOTCCommon stockHistorical · closed Apr 27, 2021CIK 1022899Updated Nov 9, 2026
Name history
Atrinsic, Inc. · through Jun 20, 2016NEW MOTION, INC. · through Jun 30, 2009MPLC, Inc. · through Apr 2, 2007MILLBROOK PRESS INC · through May 23, 2005
Current security for this SEC filerPTIX · OTC
PTIX price & chart
Historical security
This listing closed Apr 27, 2021. Live provider charts are shown only for current listings.
Current security: PTIX
About the company
Protagenic Therapeutics (Nasdaq: PTIX) is pioneering novel treatments across a range of therapeutic areas. For more information, visit www.protagenic.com.
In the news
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TXNM, SVT, INZY, PTIX on Behalf of Shareholders News provided by Halper Sadeh LLP May 19, 2025, 13:57 ET Share this article Share to X Share this article Share to X NEW YORK , May 19, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights ↗
Recent filings
10-Q filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
4 filing
4 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2026 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | — | 1,508,327Source | 5,432,642Source | — | 1,467,077Source | 3,650,370Source | 89,093Source | 2,578,558Source | 3,650,370Source | 1,955,913Source | 4,323,369Source | 8,037,420Source |
| Property, Plant and Equipment, NetUSD | — | 85,618Source | 55,982Source | — | 98,189Source | 14,556Source | 60,474Source | 110,761Source | 14,556Source | 73,046Source | 123,332Source | 1,775Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | 2,093,228Source | — | — | 2,093,228Source | — | — | — |
| Current assets: | ||||||||||||
| Assets, CurrentUSD | — | 1,422,709Source | 5,376,660Source | — | 1,368,888Source | 1,542,586Source | 89,093Source | 2,467,797Source | 1,542,586Source | 1,882,867Source | 4,200,037Source | 8,035,645Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 56,939Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | 789,320Source | 1,280,106Source | — | 674,559Source | 1,031,479Source | 5,042,052Source | 446,095Source | 1,031,479Source | 942,759Source | 655,252Source | 1,119,862Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | — | 481Source | 434Source | — | 447Source | 182Source | 54Source | 444Source | 182Source | 725Source | 444Source | 434Source |
| Additional Paid in CapitalUSD | — | 35,598,247Source | 33,871,527Source | — | 35,030,919Source | 6,991,452Source | 455,657Source | 34,720,952Source | 6,991,452Source | 37,445,495Source | 34,559,091Source | 33,371,406Source |
| Retained Earnings (Accumulated Deficit)USD | — | -34,749,473Source | -29,101,688Source | — | -34,108,688Source | -4,029,629Source | -5,397,606Source | -32,502,166Source | -4,029,629Source | -36,303,216Source | -30,777,872Source | -25,777,375Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | -130,248Source | -617,737Source | — | -130,160Source | — | -129,861Source | -86,767Source | — | -129,850Source | -113,546Source | -676,907Source |
| Stockholders' Equity Attributable to ParentUSD | -4,700,565Source | -2,470,581Source | 4,152,536Source | -3,974,011Source | -1,753,190Source | 2,618,891Source | -4,952,959Source | -1,789,166Source | 2,618,891Source | 1,013,154Source | 3,668,117Source | 6,917,558Source |
| Liabilities and EquityUSD | — | 1,508,327Source | 5,432,642Source | — | 1,467,077Source | 3,650,370Source | 89,093Source | 2,578,558Source | 3,650,370Source | 1,955,913Source | 4,323,369Source | 8,037,420Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | — | 789,320Source | 1,280,106Source | — | 674,559Source | 1,031,479Source | 5,042,052Source | 446,095Source | 1,031,479Source | 942,759Source | 655,252Source | 1,119,862Source |
| Accounts Payable, CurrentUSD | — | — | — | — | — | 949,517Source | 961,117Source | — | 949,517Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | 81,962Source | 249,063Source | — | 81,962Source | — | — | — |
| Inventory, Net | — | — | — | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2026 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 236,014Source | 161,861Source | 418,589Source | 923,139Source | 666,828Source | 864,681Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | 26Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | — | 1,038,902Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,068,017Source | -1,659,185Source | -2,806,800Source | -4,216,517Source | -3,703,776Source | -1,993,814Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 1,202,880Source | 629,883Source | 2,802,880Source | 4,775,482Source | 1,596,974Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 102,519Source | — | 3,873,653Source | 1,963,546Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -965,509Source | -456,115Source | — | 550,576Source | 1,072,704Source | -325,982Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | 1,509,178Source | 14,531Source | 1,625Source | 1,509,178Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | 418,589Source | — | — | — |
| DepreciationUSD | — | — | 12,571Source | — | 12,571Source | — | 12,572Source | 12,572Source | 49,215Source | 50,286Source | 28,218Source | 30Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | -343,399Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -1,117,778Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 287,882Source | — | 453,298Source | — | 567,736Source | 277,613Source | 332,393Source | 1,758,609Source | 1,207,107Source | 1,968,549Source |
| Investment Income, InterestUSD | — | — | 11,281Source | — | 9,291Source | — | 8,103Source | 13,867Source | — | 43,465Source | 264,476Source | 185,790Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 0Source | — | 0Source | — | — | 26,587Source | — | 26,587Source | 16,848Source | 421,738Source |
| Net Income (Loss) Attributable to ParentUSD | — | -869,496Source | -582,387Source | -5,057,523Source | -324,355Source | — | -1,440,005Source | -1,724,294Source | 1,367,977Source | -5,525,344Source | -5,000,497Source | -3,555,505Source |
| Nonoperating Income (Expense)USD | — | — | 11,281Source | — | 60,825Source | — | 8,103Source | 14,065Source | 5,871,687Source | 175,606Source | -473,523Source | 2,283Source |
| Operating ExpensesUSD | — | — | 652,066Source | — | 1,667,347Source | — | 1,448,108Source | 1,738,359Source | 4,503,710Source | 5,700,950Source | 4,526,974Source | 3,557,788Source |
| Proceeds from Contributed CapitalUSD | — | — | — | — | — | — | — | — | 3,949,732Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 125,000Source | — | 395,474Source | — | — | — |
income statement · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2026 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Operating Income (Loss)USD | — | — | — | -652,066Source | — | -1,667,347Source | -1,448,108Source | -1,738,359Source | -4,503,710Source | -5,700,950Source | -4,526,974Source | -3,557,788Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -640,785Source | — | -1,606,522Source | -1,440,005Source | -1,724,294Source | 1,367,977Source | -5,525,344Source | -5,000,497Source | -3,555,505Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -869,496Source | -582,387Source | -5,057,523Source | -324,355Source | -1,440,005Source | -1,724,294Source | 1,367,977Source | -5,525,344Source | -5,000,497Source | -3,555,505Source |
| Earnings Per Share, BasicUSD per share | — | — | — | -0.14Source | — | -0.36Source | -2.75Source | -5.44Source | 0.59Source | -1.13Source | -1.15Source | -0.82Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | -0.14Source | — | -0.36Source | -2.75Source | -5.44Source | 0.59Source | -1.13Source | -1.15Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | 4,529,096Source | — | 4,443,243Source | 523,185Source | 316,804Source | 2,328,997Source | 4,899,953Source | 4,344,580Source | 4,317,875Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 4,529,096Source | — | 4,443,243Source | 523,185Source | 316,804Source | 2,328,997Source | 4,899,953Source | 4,344,580Source | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | — | 287,882Source | — | 453,298Source | 567,736Source | 277,613Source | 332,393Source | 1,758,609Source | 1,207,107Source | 1,968,549Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 1,390,169Source | -5,526,365Source | -4,998,066Source | -3,522,834Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 107,682Source | 137,456Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | -1,495,007Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | 11,281Source | — | 9,291Source | 8,103Source | 13,867Source | — | 43,465Source | 264,476Source | 185,790Source |
| Nonoperating Income (Expense)USD | — | — | — | 11,281Source | — | 60,825Source | 8,103Source | 14,065Source | 5,871,687Source | 175,606Source | -473,523Source | 2,283Source |
| Operating ExpensesUSD | — | — | — | 652,066Source | — | 1,667,347Source | 1,448,108Source | 1,738,359Source | 4,503,710Source | 5,700,950Source | 4,526,974Source | 3,557,788Source |
| Research and Development ExpenseUSD | — | — | — | 324,352Source | — | 1,196,400Source | 880,372Source | 1,460,746Source | 901,896Source | 3,844,984Source | 3,319,867Source | 1,589,239Source |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | — | — | — | — |
Filing attachments
ex99-1.htm · 8-K · 2026-08-20
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder FDA raises no objection to the Company’s planned Phase 1 program design, dose-escalation approach, or CMC and nonclinical packages; IND submission remains on track for the fourth quarter of 2026 NEW YORK, NY - August 20, 2026 - (ACCESS Newswire) - Protagenic Therapeutics, Inc. (OTCQB: PTIX), a clinical-stage b…
Read attachment ↗ex99-1.htm · 8-K · 2025-11-26
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice New York, NY - November 26, 2025 - Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announced that it has received a notification letter from the Nasdaq Listing Qualifications Staff (the “Staff”) indicating that the Company is not in compliance with Nasdaq Listing Rules 5550(b)(1) (minimum stockholders’ equity) and 5250(c)(1) (timely f…
Read attachment ↗ex99-1.htm · 8-K/A · 2025-08-28
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 PHYTANIX BIO, INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS (IN US$) March 31, 2025 and 2024 CONTENTS Report of Independent Registered Public Accounting Firm (PCAOB ID: 6580) F-2 Consolidated Financial Statements: Consolidated F-3 Balance Sheets as of March 31, 2025 and 2024 Consolidated …
Read attachment ↗ex99-2.htm · 8-K/A · 2025-08-28
EX-99.2 4 ex99-2.htm EX-99.2 Exhibit 99.2 PROTAGENIC THERAPEUTICS, INC. PRO FORMA COMBINED BALANCE SHEETS March 31, 2025 PHYTANIX BIO, INC. AND SUBSIDIARIES PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY Adjustments Pro Forma Combined March 31, 2025 March 31, 2025 …
Read attachment ↗